Cargando…

Autoantibody profiling to follow evolution of lupus syndromes

INTRODUCTION: Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of phy...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsen, Nancy J, Li, Quan-Zhen, Quan, Jiexia, Wang, Ling, Mutwally, Azza, Karp, David R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580568/
https://www.ncbi.nlm.nih.gov/pubmed/22838636
http://dx.doi.org/10.1186/ar3927
_version_ 1782260278692413440
author Olsen, Nancy J
Li, Quan-Zhen
Quan, Jiexia
Wang, Ling
Mutwally, Azza
Karp, David R
author_facet Olsen, Nancy J
Li, Quan-Zhen
Quan, Jiexia
Wang, Ling
Mutwally, Azza
Karp, David R
author_sort Olsen, Nancy J
collection PubMed
description INTRODUCTION: Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of physicians to identify and treat early cases prior to onset of organ damaging illness. METHODS: A group of 22 patients with 4 or fewer diagnostic criteria for lupus were studied for changes in clinical and autoantibody profiles after a mean follow up period of 2.4 years. An array with more than 80 autoantigens was used to profile immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibodies. Correlations with clinical disease progression were examined. RESULTS: 3 of the 22 patients (14%) added sufficient criteria during follow up to satisfy a diagnosis of systemic lupus erythematosus (SLE) or to acquire a diagnosis of SLE renal disease. Patients who progressed were all females and were younger than those who did not progress (P=0.00054). IgG but not IgM autoreactivity showed greater increases in the progressor group than in the non-progressor group (P=0.047). IgG specificities that were higher at baseline in progressors included proliferating cell nuclear antigen (PCNA), beta 2 microglobulin, C1q and hemocyanin (P<0.019). Progressors had significant increases in La/SSB and liver cytosol type 1 (LC1) IgG autoantibodies over the period of evaluation (P≤0.0072). A quantitative risk profile generated from baseline demographic and autoantibody variables yielded highly different scores for the progressor and non-progressor groups (P=1.38 × 10(-7)) CONCLUSIONS: In addition to demographic features, autoantibody profiles using an expanded array of specificities were correlated with the risk of progressive disease in patients with lupus. These findings suggest the feasibility of developing a simple diagnostic that could be applied by nonspecialists to screen for lupus and permit effective triage for specialty care.
format Online
Article
Text
id pubmed-3580568
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35805682013-02-26 Autoantibody profiling to follow evolution of lupus syndromes Olsen, Nancy J Li, Quan-Zhen Quan, Jiexia Wang, Ling Mutwally, Azza Karp, David R Arthritis Res Ther Research Article INTRODUCTION: Identification of patients who are in early stages of lupus is currently done through clinical evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and antibody specificities that predict disease would enhance the ability of physicians to identify and treat early cases prior to onset of organ damaging illness. METHODS: A group of 22 patients with 4 or fewer diagnostic criteria for lupus were studied for changes in clinical and autoantibody profiles after a mean follow up period of 2.4 years. An array with more than 80 autoantigens was used to profile immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibodies. Correlations with clinical disease progression were examined. RESULTS: 3 of the 22 patients (14%) added sufficient criteria during follow up to satisfy a diagnosis of systemic lupus erythematosus (SLE) or to acquire a diagnosis of SLE renal disease. Patients who progressed were all females and were younger than those who did not progress (P=0.00054). IgG but not IgM autoreactivity showed greater increases in the progressor group than in the non-progressor group (P=0.047). IgG specificities that were higher at baseline in progressors included proliferating cell nuclear antigen (PCNA), beta 2 microglobulin, C1q and hemocyanin (P<0.019). Progressors had significant increases in La/SSB and liver cytosol type 1 (LC1) IgG autoantibodies over the period of evaluation (P≤0.0072). A quantitative risk profile generated from baseline demographic and autoantibody variables yielded highly different scores for the progressor and non-progressor groups (P=1.38 × 10(-7)) CONCLUSIONS: In addition to demographic features, autoantibody profiles using an expanded array of specificities were correlated with the risk of progressive disease in patients with lupus. These findings suggest the feasibility of developing a simple diagnostic that could be applied by nonspecialists to screen for lupus and permit effective triage for specialty care. BioMed Central 2012 2012-07-27 /pmc/articles/PMC3580568/ /pubmed/22838636 http://dx.doi.org/10.1186/ar3927 Text en Copyright ©2012 Olsen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Olsen, Nancy J
Li, Quan-Zhen
Quan, Jiexia
Wang, Ling
Mutwally, Azza
Karp, David R
Autoantibody profiling to follow evolution of lupus syndromes
title Autoantibody profiling to follow evolution of lupus syndromes
title_full Autoantibody profiling to follow evolution of lupus syndromes
title_fullStr Autoantibody profiling to follow evolution of lupus syndromes
title_full_unstemmed Autoantibody profiling to follow evolution of lupus syndromes
title_short Autoantibody profiling to follow evolution of lupus syndromes
title_sort autoantibody profiling to follow evolution of lupus syndromes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580568/
https://www.ncbi.nlm.nih.gov/pubmed/22838636
http://dx.doi.org/10.1186/ar3927
work_keys_str_mv AT olsennancyj autoantibodyprofilingtofollowevolutionoflupussyndromes
AT liquanzhen autoantibodyprofilingtofollowevolutionoflupussyndromes
AT quanjiexia autoantibodyprofilingtofollowevolutionoflupussyndromes
AT wangling autoantibodyprofilingtofollowevolutionoflupussyndromes
AT mutwallyazza autoantibodyprofilingtofollowevolutionoflupussyndromes
AT karpdavidr autoantibodyprofilingtofollowevolutionoflupussyndromes